Vnitr Lek 2020, 66(6):335-339 | DOI: 10.36290/vnl.2020.098

Anaphylaxis - acute and long-term management

Martina Vachová
Ústav imunologie a alergologie, Lékařská fakulta v Plzni, Univerzita Karlova

Anaphylaxis is a serious, potentially life-threatening condition, and all healthcare professionals should be aware of it. Prompt recognition of anaphylaxis signs and early initiation of adequate treatment are essential for successful acute management. The first-line treatment is the administration of intramuscular adrenalin, followed by other interventions. Patients should be monitored after recovery for possible biphasic reaction. Before discharge, the individual risk of further reaction should be assessed and where appropriate an adrenalin auto-injector should be prescribed. Allergy specialist follow-up is essential for the identification of possible triggers and cofactors. Elimination of these factors reduces the risk of future reactions. Useful preventive measure is allergen immunotherapy, which is definitely indicated in patients with anaphylaxis induced by an insect sting.

Keywords: anaphylaxis, trigger, cofactor, adrenaline auto‑injector, allergen immunotherapy.

Published: October 8, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vachová M. Anaphylaxis - acute and long-term management. Vnitr Lek. 2020;66(6):335-339. doi: 10.36290/vnl.2020.098.
Download citation

References

  1. Muraro A, Roberts G, Worm M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy. 2014; 69(8): 1026-1045. Go to original source... Go to PubMed...
  2. Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol. 2017; 140(2): 335-348. Go to original source... Go to PubMed...
  3. Petrů V. Anafylaxe - život ohrožující reakce. Postgrad Med 2019; 21(4): 277-282.
  4. Muraro A, Lemanske Jr. RF, Castells et al. Precision medicine in allergic disease‑food allergy, drug allergy, and anaphylaxis‑PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy 2017; 72: 1006-1021. Go to original source... Go to PubMed...
  5. Panesar SS, Javad S, de Silva D, et al. The epidemiology of anaphylaxis in Europe: a systematic review. Allergy. 2013; 68: 1353-1361. Go to original source... Go to PubMed...
  6. Lee S, Hess EP, Lohse C, et al. Trends, characteristics, and incidence of anaphylaxis in 2001-2010: a population‑based study. J Allergy Clin Immunol. 2017; 139: 182-188. Go to original source... Go to PubMed...
  7. Ruiz Oropeza A, Bindslev‑Jensen C, Broesby‑Olsen S, et al. Patterns of anaphylaxis after diagnostic workup: A follow‑up study of 226 patients with suspected anaphylaxis. Allergy. 2017; 72: 1944-1952. Go to original source... Go to PubMed...
  8. Grabenhenrich LB, Dölle S, Moneret‑Vautrin A, et al. Anaphylaxis in children and adolescents: The European Anaphylaxis Registry. J Allergy Clin Immunol. 2016; 137(4): 1128-1137. Go to original source... Go to PubMed...
  9. Simons FE, Ardusso LR, Bilò MB, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011; 4(2): 13-37. Go to original source... Go to PubMed...
  10. Ellis AK, Day JH. Incidence and characteristics of biphasic anaphylaxis: a prospective evaluation of 103 patients. Ann Allergy Asthma Immunol. 2007; 98(1): 64-69. Go to original source... Go to PubMed...
  11. Akin C. Mast cell activation syndromes. J Allergy Clin Immunol. 2017; 140(2): 349-355. Go to original source... Go to PubMed...
  12. Sala‑Cunill A, Cardona V, Labrador‑Horrillo M, et al. Usefulness and limitations of sequential serum tryptase for the diagnosis of anaphylaxis in 102 patients. Int Arch Allergy Immunol. 2013; 160(2): 192-199. Go to original source... Go to PubMed...
  13. Petrů V. Doporučený postup léčby anafylaktické reakce - aktualizace 2019. Alergie 2019; 21(3): 216-219.
  14. Worm M, Francuzik W, Renaudin JM, et al. Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry. Allergy. 2018; 73(6): 1322-1330. Go to original source... Go to PubMed...
  15. Vachová M. Alergie na blanokřídlý hmyz. Postgrad Med 2019; 21(4): 291-296.
  16. Doporučení výboru České společnosti alergologie a klinické imunologie k použití adrenalinového autoinjektoru. Alergie 2018; 20(4): 260.
  17. Ellis BC, Brown SG. Parenteral antihistamines cause hypotension in anaphylaxis. Emerg Med Australas. 2013; 25(1): 92-93. Go to original source... Go to PubMed...
  18. Bilò MB, Cichocka‑Jarosz E, Pumphrey R, et al. Self‑medication of anaphylactic reactions due to Hymenoptera stings‑an EAACI Task Force Consensus Statement. Allergy. 2016; 71(7): 931-943. Go to original source... Go to PubMed...
  19. Vachová M. Alergie na včelí a vosí jed. Remedia 2020; 30: 68-70.
  20. Vachová M, Panzner P, Malkusová I, et. al. Utility of laboratory testing for the diagnosis of Hymenoptera venom allergy. Allergy Asthma Proc. 2016; 37(3): 248-255. Go to original source... Go to PubMed...
  21. Vachová M, Panzner P, Kopač P, et al. Routine clinical utility of honeybee venom allergen components. J Allergy Clin Immunol Pract. 2018; 6(6): 2121-2123. Go to original source... Go to PubMed...
  22. Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy. 2018; 73(4): 744-764. Go to original source... Go to PubMed...
  23. Bělohlávková S. Potravinová alergie v roce 2019. Postgrad Med 2019; 21(4): 283-289.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.